While research suggests having a higher weight may increase your risk for certain conditions, people can be healthy at every ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight ...

On a weekday morning in Dublin, a group of patients walked into a weight-loss clinic hoping to shed pounds. What they didn’t expect was to also lose their taste for alcohol. A new study has found that ...

Respondents see the glucagon-like peptide 1 (GLP-1) drugs as a major advance. They also have concerns about whether insurers ...

Viking Therapeutics offers leaner operations, lower complexity, faster trial execution, and less execution risk. Learn more ...

Lehigh Valley health experts discuss obesity, energy management, Medicaid changes, and GLP-1 drug trends at LVBCH’s 45th ...

Glucagon-like peptide-1 receptor agonists are tied to a reduction in alcohol intake in patients being treated for obesity.

Patients with diabetes mellitus who use GLP-1 RAs have an increased risk for acute and chronic pancreatitis, according to a study presented at DDW 2025.

SaveHealth explores the historical trajectory of weight loss drugs, examining their scientific basis, regulatory battles, ...

Balancing best practices with patient affordability and literacy. Here’s how one doctor adapts treatment plans for real-world ...

Viking Therapeutics' VENTURE-Oral study of VK2735 has completed enrollment, with a readout set for H2'25. Learn why VKTX ...

First-generation GLP-1 drugs have found to cut down the risk of obesity-related cancers by 41%, outperforming weight-loss ...